Recombinant Human LILRA1/CD85i/LIR-6 Protein, CF

WhenRecombinant Human LILRA1/CD85i/LIR-6 (Catalog # 9226-T4) is coated at 2 µg/mL,Recombinant Human Angiopoietin-likeProtein 7/ANGPTL7 (Catalog # 914-AN) binds with anED50 of0.3-1.8 µg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LILRA1/CD85i/LIR-6 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LILRA1/CD85i/LIR-6 (Catalog # 9226-T4) is coated at 2 µg/mL, Recombinant Human Angiopoietin-like 7/ANGPTL7 (Catalog # 914-AN) binds with an ED 50 = 0.3-1.8 µg/mL.
• Source: Mouse myeloma cell line, NS0-derived human LILRA1/CD85i/LIR-6 protein Pro17-Asn461, with a C-terminal 6-His tag
• Accession #: O75019
• N-terminal Sequence: Pro17 & Gly24
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 49 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 62-76 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 3 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LILRA1/CD85i/LIR-6 Protein, CF

• CD85 antigen-like family member I
• CD85i antigen
• CD85i
• leukocyte immunoglobulin-like receptor subfamily A member 1 soluble isoform
• leukocyte immunoglobulin-like receptor subfamily A member 1
• leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1
• LILRA1
• LIR6
• LIR-6
• LIR-6Leukocyte immunoglobulin-like receptor 6
• LIR6MGC126563

Background

LILRA1, also known as CD85i and LIR-6, is an approximately 70 kDa variably glycosylated transmembrane protein that regulates immune cell activation (1). Mature human LILRA1 consists of a 445 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 7 aa cytoplasmic tail (2). The transmembrane segment contains a positively charged arginine which may mediate association with signaling molecules. Alternative splicing generates an isoform that lacks the third and fourth Ig-like domains (2). LILRA1 is expressed on monocytes (3, 4) and binds to the free heavy chain of the MHC class I molecule HLA-B27 (4, 5). It is activated in response to the BCG mycobacterial strain (6). R&D Systems in-house testing indicates that LILRA1 binds to Angiopoietin-like 7, consistent with the demonstrated functional interactions between other members of these protein families (7).

1. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
2. Borges, L. et al. (1997) J. Immunol. 159:5192.
3. Tedla, N. et al. (2008) J. Leukoc. Biol. 83:334.
4. Allen, R.L. et al. (2001) J. Immunol. 167:5543.
5. Jones, D.C. et al. (2011) J. Immunol. 186:2990.
6. Hogan, L.E. et al. (2016) Sci Rep. 6:21780.
7. Zheng, J. et al. (2012) Nature 485:656.

Bioinformatics

• Uniprot:
  • O75019()